

Product Name: SU5416 Revision Date: 02/21/2024

Product Data Sheet

SU5416

Cat. No.: A3847

CAS No.: 204005-46-9 **Formula:** C15H14N2O


M.Wt: 238.28

Synonyms: Semaxinib; SU-5416; SU 5416

Target: Tyrosine Kinase

Pathway: c-RET

Storage: Desiccate at -20°C



Solvent & Solubility

insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL in DMSO

In Vitro

| Preparing Stock Solutions | Solvent Concentration | 1mg | 5mg | 10mg |
|---------------------------|-----------------------|-----------|------------|------------|
| | 1 mM | 4.1967 mL | 20.9837 mL | 41.9674 mL |
| | 5 mM | 0.8393 mL | 4.1967 mL | 8.3935 mL |
| | 10 mM | 0.4197 mL | 2.0984 mL | 4.1967 mL |

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

| Shortsummary | VEGF receptor inhibitor a | VEGF receptor inhibitor and AHR agonist | | |
|---------------------------|---------------------------|--|--|--|
| IC ₅₀ & Target | 1.23 μM (VEGFR) | | | |
| | Cell Viability Assay | BE gree return | | |
| In Vitro | Cell Line: | HUVECs | | |
| | Preparation method: | The solubility of this compound in DMSO is > 11.9 mg/mL. General tips for | | |
| | | obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes | | |
| | | and/or shake it in the ultrasonic bath for a while. Stock solution can be stored | | |
| | | below - 20 °C for several months. | | |
| | Reacting conditions: | 0.01 ~ 100 μM; 2 days | | |
| | | 4 Lynny anayht aam | | |

| | | † | | |
|---------|-------------------|---|--|--|
| | Applications: | In HUVECs, SU5416 dose-dependently inhibited VEGF- and FGF-driven | | |
| | | mitogenesis, with the IC50 values of 0.04 \pm 0.02 μM and 50 μM , respectively. | | |
| | | SU5416 showed > 1000-fold selectivity over VEGF- driven mitogenesis than | | |
| | | FGF-driven mitogenesis. | | |
| | Animal experiment | | | |
| | Animal models: | Female BALB/c nu/nu mice bearing A375 cell xenografts | | |
| | Dosage form: | 1 ~ 25 mg/kg; i.p.; q.d., for 39 days | | |
| | Applications: | In BALB/c nu/nu mice bearing A375 cell xenografts, SU5416 at the dose of 3 | | |
| In Vivo | | mg/kg/day significantly inhibited tumor growth. SU5416 at the dose of 25 | | |
| | | mg/kg/day resulted in a > 85% inhibition of tumor growth with no mortality. | | |
| | Other notes: | Please test the solubility of all compounds indoor, and the actual solubility may | | |
| | | slightly differ with the theoretical value. This is caused by an experimental | | |
| | | system error and it is normal. | | |

APE BIO

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59(1):99-106.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



Active balletion to page the buscom

AREI BIO

ARE EN ENDER DE UNION

ARE ENGINEERING THE PROPERTY OF THE PROPERTY O

A P E 1 June of the Internal o

ARE LEGISLATION TO DO THE OWNERS AND ADDRESS OF THE OWNERS AND ADDRESS